This commentary addresses the clinical challenge of determining optimal titration endpoints for ADHD medications to balance efficacy with tolerability.
A network meta-analysis of ADHD pharmacological interventions provides evidence to guide clinical guidelines and shared decision-making regarding optimal medication dosage and titration strategies.
This systematic review of 122 studies finds that most demographic and clinical variables do not reliably predict antidepressant response to ketamine or esketamine, with only early response and family history of substance use disorders showing promise for future investigation.
A meta-analysis indicates no causal link between antidepressant use during pregnancy and neurodevelopmental disorders, providing reassurance for prescribing decisions in pregnant patients.
A meta-analysis indicates no causal link between antidepressant use during pregnancy and neurodevelopmental disorders, providing reassurance for prescribing decisions in pregnant patients.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Mar 25 – Jun 01)
- When treating ADHD, avoid escalating doses beyond established optimal ranges as network meta-analyses show minimal additional clinical benefit.
- Consider sex- and hormone-informed dosing strategies for antipsychotics, as hormonal status significantly influences pharmacokinetics and efficacy in women.
- Reassure pregnant patients with depression that current evidence indicates no causal link between antidepressant use and neurodevelopmental disorders in offspring.
- Monitor for new-onset depression in patients receiving sevoflurane anesthesia, as it is associated with a significantly higher long-term risk compared to propofol.
- Initiate medications for alcohol use disorder promptly upon hospitalization, given that only 30% of AUD-related admissions currently receive evidence-based pharmacotherapy.
- Be aware that chronic nitrous oxide use can cause protracted encephalopathy requiring vitamin B12, with limited long-term outcome data for psychiatric comorbidities.
- Utilize early response to ketamine/esketamine and family history of substance use disorders as potential predictors for antidepressant response, as most other demographic variables are unreliable.
- Recognize that a single 25 mg dose of psilocybin can produce rapid, clinically meaningful symptom reductions for depression within 48 hours.
- Understand that the antidepressant effects of a single psilocybin dose can be sustained for over three months due to persistent changes in brain connectivity.
- Apply formulation science principles when optimizing stimulant therapy for ADHD to better manage medication delivery and efficacy.
Diagnosis & Treatment 2
A single dose of psilocybin provides sustained antidepressant effects for over three months, highlighting its potential as a rapid-acting treatment for depression.
A single dose of psilocybin induces rapid remission in depression, highlighting its potential as a novel pharmacological intervention for treatment-resistant mood disorders.
Journal Article 3
A network meta-analysis in The Lancet Psychiatry identifies optimal dosage ranges for five common ADHD medications, demonstrating minimal clinical benefit beyond specific dose limits.
This article analyzes the quality of evidence and efficacy of interventions for common mental disorders within Cochrane reviews, providing a high-level overview of evidence quality rather than specific pharmacological data.
A study of Veterans Health Administration data reveals that only 30% of hospitalizations for alcohol use disorder result in the initiation of medications for AUD, highlighting a significant gap in evidence-based pharmacotherapy implementation.
Policy & Regulation 1
This article highlights a new clozapine guideline, which is directly relevant to psychiatric prescribing, alongside unrelated topics on paternal health and obesity.
Clinical Pearl 2
A randomized clinical trial demonstrates that a single 25 mg dose of psilocybin produces rapid, clinically meaningful symptom reductions for depression within 48 hours, suggesting a potential alternative to daily antidepressants.
Research identifies optimal dosage ranges for ADHD medications, indicating that increasing doses beyond specific limits yields minimal additional therapeutic benefit.
Drug Development 1
A Phase 2 trial demonstrates that a single dose of psilocybin provides rapid relief of depression symptoms, supporting its potential as a rapid-acting antidepressant therapy.
Mechanism of Action 2
A single dose of psilocybin induces persistent changes in brain connectivity lasting up to a month, providing mechanistic insight into the long-lasting effects of this psychedelic treatment for psychiatric disorders.
This preclinical study elucidates the spatial transcriptomic mechanisms of SSRIs in dorsal raphe neurons, revealing cell-type-specific heterogeneity and opposing transcriptional changes in neuropeptides that inform the molecular basis of SSRI efficacy.
Substance Use 1
This case report highlights protracted encephalopathy from chronic nitrous oxide use, emphasizing that while vitamin B12 is the standard treatment, long-term outcome data is limited and comorbid psychiatric conditions complicate management.